



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
SECOND QUARTER OF 2019 (2019Q2)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**



This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.




Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2018Q2	2019Q1	2019Q2	Quarterly % Change 2019Q1 vs 2019Q2	Quarterly % Change 2018Q2 vs 2019Q2
Total number of controlled substance patients	236,400	234,193	225,162	-3.9%	-4.8%
Number of patients receiving opioids	154,145	153,396	143,902	-6.2%	-6.6%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	330,051	323,222	306,808	-5.1%	-7.0%
Number of buprenorphine/naloxone prescriptions filled	22,824	23,628	24,504	3.7%	7.4%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	39,331	35,002	33,553	-4.1%	-14.7%
Total MME of opioids filled - excluding buprenorphine/naloxone	296,877,603	274,456,795	266,371,805	-2.9%	-10.3%
Total MME/prescription-day	56	55	55	0.1%	-1.7%
Number of patients receiving benzodiazepines	87,490	82,765	80,916	-2.2%	-7.5%
Number of benzodiazepine prescriptions filled	192,903	182,677	177,703	-2.7%	-7.9%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	33,658	31,522	30,241	-4.1%	-10.2%
Total DME of benzodiazepines filled	103,503,807	94,408,678	91,292,304	-3.3%	-11.8%
Total DME/patient	1,183	1,141	1,128	-1.1%	-4.6%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2018Q2	2019Q1	2019Q2	Quarterly % Change 2019Q1 vs 2019Q2	Quarterly % Change 2018Q2 vs 2019Q2
High dose opioids (>=90 MME/day)	14,065	12,319	11,762	-4.5%	-16.4%
High dose benzodiazepines (>=40 DME/day)	14,870	13,824	13,332	-3.6%	-10.3%
Opioids >=90 days and <90% of days in past 6 months	20,460	18,479	17,699	-4.2%	-13.5%
Opioids >=90% of days in past 6 months	31,031	30,080	29,519	-1.9%	-4.9%
Benzodiazepines >=90 days and <90% of days in past 6 months	23,123	21,262	20,563	-3.3%	-11.1%
Benzodiazepines >=90% of days in past 6 months	24,984	23,619	23,142	-2.0%	-7.4%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	3,752	3,374	3,059	-9.3%	-18.5%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	2,386	2,097	1,842	-12.2%	-22.8%
Concurrent opioid and benzodiazepines (>=10 days overlap)	19,767	17,000	15,840	-6.8%	-19.9%
High dose opioids (>=90 MME/day) plus benzodiazepines	3,643	3,135	2,873	-8.4%	-21.1%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	2,627	2,269	2,137	-5.8%	-18.7%
New Opioid Patients with at least 30 days of coverage in the past 3 months	3,403	2,803	2,563	-8.6%	-24.7%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	4,421	4,151	3,874	-6.7%	-12.4%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2018Q2	2019Q1	2019Q2	Quarterly % Change 2019Q1 vs 2019Q2	Quarterly % Change 2018Q2 vs 2019Q2
Total active controlled substance prescribers	3,076	3,213	3,156	-1.8%	2.6%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	62	60	57	-5.0%	-8.1%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	144	137	134	-2.2%	-6.9%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	24	9	7	-22.2%	-70.8%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,164	1,463	1,628	11.3%	39.9%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	551	469	344	-26.7%	-37.6%
Number of Patients with PMP reports requested by practitioners	126,099	169,107	227,340	34.4%	80.3%
% of Chronic opioid users with a PMP request in the past 3 months*	66.3%	74.7%	79.1%	5.9%	19.4%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	43.0%	51.6%	55.9%	8.5%	30.0%
% of New Opioid Patients with a PMP request in the past 3 months**	19.3%	24.9%	32.5%	30.3%	68.5%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	23.0%	29.9%	35.6%	19.1%	54.3%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures

Year and Quarter	2018Q2	2019Q1	2019Q2	Quarterly % Change 2019Q1 vs 2019Q2	Quarterly % Change 2018Q2 vs 2019Q2
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	155	189	196	3.7%	26.5%
Buprenorphine/naloxone patients (>=10 days)	5,895	6,282	6,480	3.2%	9.9%
Buprenorphine/naloxone prescriptions filled	22,824	23,628	24,504	3.7%	7.4%
Total Practitioners with DATA Waiver	580	698	726	4.0%	25.2%
Nurse Practitioners and PA's with DATA Waiver	114	174	191	9.8%	67.5%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	5,152	5,541	5,183	-6.5%	0.6%
Number of distinct NM Medicaid providers of methadone	11	12	11	-8.3%	0.0%

Methadone Treatment Programs by Survey Date	1/2018	3/2018	8/2018	12/2018	3/2019
Number of Methadone Treatment Programs	15	16	16	16	17
Number of Methadone Treatment Patients in those Programs	5,275	5,562	6,259	6,641	6,696


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2018Q2	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q2 vs 2019Q1
New Enrollments in NM State Government Naloxone Programs	1,447	1,644	2,367	44.0%	63.6%
Total Number of NM Naloxone Doses distributed	8,456	10,768	15,608	44.9%	84.6%
Total Number of NM Reported Reversals	504	1,017	1,170	15.0%	132.1%

Year and Quarter	2018Q2	2018Q4	2019Q1	Quarterly % Change 2018Q4 vs 2019Q1	Quarterly % Change 2018Q2 vs 2019Q1
Pharmacies Presenting Medicaid Naloxone Claims	210	234	288	23.1%	37.1%
Number of Medicaid Naloxone Claims Processed	1,697	1,712	3,737	118.3%	120.2%

Some naloxone doses were given to organizations and may not have been distributed in that quarter.

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 369 outpatient Pharmacies with a NM address in 2017 according to the Board of Pharmacy.

All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

